about
N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate CancerA Systematic Assessment of Accuracy in Detecting Somatic Mosaic Variants by Deep Amplicon Sequencing: Application to NF2 Gene.Discovering chimeric transcripts in paired-end RNA-seq data by using EricScript.Bioinformatics for next generation sequencing data.H3M2: detection of runs of homozygosity from whole-exome sequencing data.A shifting level model algorithm that identifies aberrations in array-CGH data.A very fast and accurate method for calling aberrations in array-CGH data.CEBPA-double-mutated acute myeloid leukemia displays a unique phenotypic profile: a reliable screening method and insight into biological features.EXCAVATOR: detecting copy number variants from whole-exome sequencing dataDetecting common copy number variants in high-throughput sequencing data by using JointSLM algorithm.Sphingosine 1-phosphate induces differentiation of mesoangioblasts towards smooth muscle. A role for GATA6372 kb microdeletion in 18q12.3 causing SETBP1 haploinsufficiency associated with mild mental retardation and expressive speech impairment.WNP: a novel algorithm for gene products annotation from weighted functional networks.Expanding the mutational spectrum of LZTR1 in schwannomatosis.Thin and thick primary cutaneous melanomas reveal distinct patterns of somatic copy number alterations.SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer.A novel brain tumour model in zebrafish reveals the role of YAP activation in MAPK- and PI3K-induced malignant growth.Clinical significance of rare copy number variations in epilepsy: a case-control survey using microarray-based comparative genomic hybridization.16p11.2 de novo microdeletion encompassing SRCAP gene in a patient with speech impairment, global developmental delay and behavioural problems.Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer.Validation of a method for noninvasive prenatal testing for fetal aneuploidies risk and considerations for its introduction in the Public Health System.Multilineage dysplasia as assessed by immunophenotype has no impact on clinical-biological features and outcome of NPM1-mutated acute myeloid leukemia.EX-HOM (EXome HOMozygosity): a proof of principle.A systematic analysis of bone marrow cells by flow cytometry defines a specific phenotypic profile beyond GPI deficiency in paroxysmal nocturnal hemoglobinuria.Immunotherapy Bridge 2016 and Melanoma Bridge 2016: meeting abstracts.Contemporary genetic testing in inherited cardiac disease: tools, ethical issues, and clinical applications.Hypovitaminosis D and osteopenia/osteoporosis in a haemophilia population: a study in HCV/HIV or HCV infected patients.Differential impact of RB status on E2F1 reprogramming in human cancer.A novel founder MYO15A frameshift duplication is the major cause of genetic hearing loss in Oman.Mechanisms of Resistance to CDK4/6 Inhibitors in Breast Cancer and Potential Biomarkers of Response.Tumor purity quantification by clonal DNA methylation signatures.Novel α-actinin 2 variant associated with familial hypertrophic cardiomyopathy and juvenile atrial arrhythmias: a massively parallel sequencing study.Exome sequencing in primary melanoma identifies novel drivers of melanoma progression.Patient derived organoids to model rare prostate cancer phenotypes.ddSeeker: a tool for processing Bio-Rad ddSEQ single cell RNA-seq dataA gene expression signature of Retinoblastoma loss-of-function predicts resistance to neoadjuvant chemotherapy in ER-positive/HER2-positive breast cancer patientsGenome-wide plasma DNA methylation features of metastatic prostate cancerPlasma Thymidine Kinase Activity as a Biomarker in Patients with Luminal Metastatic Breast Cancer Treated with Palbociclib within the TREnd TrialComprehensive analysis of radiomic datasets by RadAR
P50
Q28771715-3A7AFBCD-44FA-4730-98DC-4D0872C05667Q30408869-3DD13118-7CD2-4236-A054-4BCDE0BE153DQ30574550-ABB8ABD2-4F20-4597-948F-B799318BC734Q30795509-F8B4BCD3-86BD-409F-8B2F-FFAA008BCC8BQ30833450-0232904F-251A-4281-A624-69579B424165Q33516916-92FB06CC-4F4A-4B4D-8063-7A48DDC8AB37Q33537635-2353E69C-23F8-4D93-BD77-58EF597BD04CQ33573806-3BF63388-1064-4909-817E-F56CD14E0286Q33742574-F54A6C5D-F239-45A7-A626-B2AC1BDBE9E7Q33820514-8E740E9B-DB6F-4C50-9195-CEC05CC4CEFCQ33918167-8F562B7B-A764-4565-B9D8-D98886F7A38BQ34254326-14F3DCBC-24A5-47E1-8FDD-429097BF6049Q34325782-F188B0DF-4FD7-400D-9902-44A60E276F7CQ35722195-58CB48D9-050A-4C6C-99E6-381E2646BACCQ37327493-6E31DCE7-E39F-4FBB-B37C-EACE4BF9F734Q37595372-EF171017-4B5D-41DF-91AB-EE4A68D68314Q37612660-A47AB29A-E81D-42D8-A325-E46E57350935Q37956210-9EE2BA4C-985B-4D65-84E6-0511A7D5C424Q38275896-F1DA0854-FEC5-4519-83DE-BA14C78E6F80Q38768101-623DD5DD-91E5-4738-8CA1-BDF5B6376C3CQ39735567-4999834D-4A0B-4883-92B5-06918135EF8DQ40809704-EEB2B2BB-8C51-4D55-952F-0B48AF9C98F0Q42613349-5D62EED8-A820-4C23-9E28-3680B4EBA498Q43650499-424214D8-6803-4739-8DE6-BF8AEF9614B0Q45785941-FDF16F9D-1E0A-4E24-AC98-16B3E2560311Q45875036-18F8A560-855B-4CD4-A4E8-483D4F3585E4Q45880333-8E8C9D65-175E-4BA0-A043-8344CF4C852AQ46068832-E969279E-432B-402B-BE16-0259D080C11FQ47268315-F8CB69F1-5103-4C5F-82A2-A8E6AD0866BBQ47321016-9C8964FB-3DCF-4DE1-8637-350FA723E1E5Q48541245-C4F116C7-61FE-4501-8B3C-972FFC0EEF59Q55058506-045DF004-E1D8-41D9-AEB2-A063445F274EQ55159957-E2AE960F-0FA4-4D86-ABB4-81C0CA987FCBQ55367999-3B67E438-2ABD-48A4-87DB-44608D814EBDQ60934727-551764D4-5E1D-4EAD-834B-FB5E1617E3FDQ88128688-754681A3-D17C-4975-BD51-2CAFC99E4D79Q90156187-8260B6CF-74FA-4CF4-BB16-8906BA830B72Q92641812-076149EE-9F58-4E27-9300-749110EFD067Q96429331-C8901676-C7FE-4B64-BEAF-B472152B93BE
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Matteo Benelli
@ast
Matteo Benelli
@en
Matteo Benelli
@es
Matteo Benelli
@nl
type
label
Matteo Benelli
@ast
Matteo Benelli
@en
Matteo Benelli
@es
Matteo Benelli
@nl
prefLabel
Matteo Benelli
@ast
Matteo Benelli
@en
Matteo Benelli
@es
Matteo Benelli
@nl
P106
P1153
36163853600
P2456
P31
P496
0000-0003-1227-356X